Clinique Neuro-Outaouais
Quick facts
Phase 3 pipeline
- efgartigimod administration · Autoimmune diseases
Efgartigimod is a monoclonal antibody that targets and depletes neonatal Fc receptor (FcRn) to reduce immunoglobulin G (IgG) levels.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: